Q-omics provides the consensus-scored ZXDB profile across patient tissues and cancer cell-line models. ZXDB expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZXDB is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, ZXDB RNA expression shows 20,745 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, COAD, and THYM as cancer lineages where ZXDB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZXDB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZXDB survival associations across molecular data types. ZXDB RNA expression shows survival associations in the most cancer types (27), followed by mutation status (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZXDB RNA expression–survival associations across cancer types. High ZXDB expression shows unfavorable associations in KIRP, LUAD and THCA, but favorable associations in KIRC, ACC and MESO. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZXDB RNA expression.
This table summarizes ZXDB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for ZXDB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZXDB shows lower tumor expression in THCA, BLCA and UCEC and higher tumor expression in COAD, HNSC and BRCA. The COAD box plot shows higher ZXDB RNA expression in tumor versus normal tissue (log2 FC = +0.580, t-test p < 0.001).
This table shows molecular features associated with ZXDB in patient tissues and cancer cell lines. In patient samples, ZXDB shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZXDB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
